CD123 targeted CAR-NK cells vs Pivekimab Sunirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline

CD123 targeted CAR-NK cells

Developed by Chongqing Precision Biotech Co., Ltd

Phase 1/2 in Acute Myeloid Leukemiacell therapy (CAR-NK)
Weak signal

NCT06006403 · Phase 1/2 · completed

This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.

Next expected readout: June 2027 · NCT06690827 (registry estimate)

No aligned efficacy figure on record for this race.

Pivekimab Sunirine · Decnupaz

Marketed by AbbVie

Phase 2/3 in Acute Myeloid Leukemiaantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT04086264 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCD123 targeted CAR-NK cellsPivekimab Sunirine
OS, median—Not reported—Trial running · NCT07581002
Complete remission—Not reported—Trial running · NCT07581002
Event-free survival, median—Not reported—Trial running · NCT07581002
Duration of response, median—Not reported—Trial running · NCT07581002

OS, median

CD123 targeted CAR-NK cells
—Not reported
Pivekimab Sunirine
—Trial running · NCT07581002

Complete remission

CD123 targeted CAR-NK cells
—Not reported
Pivekimab Sunirine
—Trial running · NCT07581002

Event-free survival, median

CD123 targeted CAR-NK cells
—Not reported
Pivekimab Sunirine
—Trial running · NCT07581002

Duration of response, median

CD123 targeted CAR-NK cells
—Not reported
Pivekimab Sunirine
—Trial running · NCT07581002
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CD123 targeted CAR-NK cells: no structured comparison results are available for Acute Myeloid Leukemia.

Pivekimab Sunirine: no structured comparison results are available for Acute Myeloid Leukemia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CD123 targeted CAR-NK cells's landscape · Pivekimab Sunirine's landscape